Home
/ Ablynx
/ Competitors

Ablynx Competitors and Similar CompaniesClear all

Ablynx's competitors and similar companies include ImmunoGen and Genfit.

	Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.	ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.	Genfit GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs.
Founding Date	Founding Date 2001	Founding Date 1981	Founding Date 1999
Type	Type Subsidiary	Type Public	Type Public
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology	Tags Healthcare biotech drug development medical diagnostics pharma
Locations	Locations Gent, BE HQ	Locations Waltham, US HQ	Locations Loos, FR HQ Cambridge, US
Employees	Employees 1252% decrease	Employees 277161% increase	Employees 180
Valuation ($)	Valuation ($) N/A	Valuation ($) 8.7 b	Valuation ($) 280.8 m
Financial
Revenue (est.)	Revenue (est.) €85.2m (FY, 2016)	Revenue (est.) $108.8m (FY, 2022)	Revenue (est.) €65.4m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods $176k (FY, 2022)	Cost of goods €302k (FY, 2025)
Gross profit	Gross profit N/A	Gross profit $108.6m (FY, 2022)	Gross profit €70.8m (FY, 2025)
Net income	Net income (€1.1m) (FY, 2016)	Net income ($222.9m) (FY, 2022)	Net income (€86m) (FY, 2025)
Operating ⚠
Patents (Foreign)	Patents (Foreign) 180 (Q2, 2017)	Patents (Foreign) N/A	Patents (Foreign) 450 (FY, 2019)
Patents (US)	Patents (US) 50 (Q2, 2017)	Patents (US) N/A	Patents (US) 28 (FY, 2019)
Funding
Total funding raised	Total funding raised $ 498.8m	Total funding raised $ 56m	Total funding raised N/A